TRIO Pharmaceuticals raised $3.1 million in a pre-Series A financing round led by Friedman Bioventure Fund to advance cancer therapeutics.
TRIO Pharmaceuticals raised $3.1 million in a pre-Series A financing round led by Friedman Bioventure Fund to advance cancer therapeutics.
12/03/24, 2:11 PM
Location
san diegoMoney raised
$3.1 million
Industry
biotechnology
Round Type
series a
Investors
Life Science Angels, Nu Fund Venture Group, Multiple Myeloma Research Foundation, Friedman Bioventure Fund
TRIO Pharmaceuticals has successfully completed a $3.1 million pre-Series A financing round, focused on developing bispecific antibodies for cancer treatment. The funding was led by Friedman Bioventure Fund, with additional support from the Multiple Myeloma Research Foundation and other investors.
Company Info
Location
11956 bernardo plaza drive, suite 160
san diego, california, united states
Additional Info
TRIO Pharmaceuticals, Inc. is a cancer immunotherapeutics company pioneering bispecific antibodies for the treatment of cancer with unprecedented potency and selectivity. TRIO’s innovative antibody drugs directly stop tumor growth without affecting normal cells and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. TRIO is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells. TRIO has an experienced team that has developed first-in-class FDA-approved drugs.